Improved risk stratification by the integration of the revised International Prognostic Scoring System with the Myelodysplastic Syndromes Comorbidity Index von van Spronsen, M.F, Ossenkoppele, G.J, Holman, R, van de Loosdrecht, A.A

Volltext

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the... von Russell, Nigel, Douglas, Kenny, Ho, Anthony D, Mohty, Mohamad, Carlson, Kristina, Ossenkoppele, G J, Milone, Giuseppe, Pareja, Macarena Ortiz, Shaheen, Daniel, Willemsen, Arnold, Whitaker, Nicky, Chabannon, Christian

Volltext

Response to letter commenting on: Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scorin... von van Spronsen, M.F, Witte, B.I, Ossenkoppele, G.J, Westers, T.M, van de Loosdrecht, A.A

Volltext

High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2 von Chamuleau, M.E.D, Ossenkoppele, G.J, van Rhenen, A, van Dreunen, L, Jirka, S.M.G, Zevenbergen, A, Schuurhuis, G.J, van de Loosdrecht, A.A

Volltext

The war on clones: a Darwinian enigma von Cloos, J., Ossenkoppele, G.J.

Volltext

P-095 A five parameter based flow cytometric scoring system refines the revised International Prognostic Scoring System for myelodysplastic syndromes von Alhan, C, Westers, T.M, Cremers, E.M.P, Cali, C, Ossenkoppele, G.J, Van de Loosdrecht, A.A

Volltext

P-078 Flow cytometry has a high negative predictive value for excluding MDS in patients with cytopenia and indeterminate cytomorphology and cytogenetics von Cremers, E.M.P, Westers, T.M, Alhan, C, Wondergem, M.J, Cali, C, Schouten, C.W.M, Ossenkoppele, G.J, Van de Loosdrecht, A.A

Volltext

62 MUTATIONS IN EPIGENETIC REGULATORS ARE SIGNIFICANTLY ASSOCIATED WITH ABERRANT EXPRESSION OF MYELOID DIFFERENTIATION ANTIGENS ON MYELOID PROGENITOR CELLS IN LOW/INTERMEDIATE RISK... von Coelho, P. Silva, Cremers, E.M.P, Westers, T.M, de Graaf, A.O, Alhan, C, Cali, C, Visser-Wisselaar, H.A, Chitu, D.A, Vellenga, E, Klein, S.K, Wijermans, P.W, de Greef, G.E, Legdeur, M.C, Muus, P, Ossenkoppele, G.J, Stevens-Kroef, M.J.P.L, van der Reijden, B, Jansen, J.H, van de Loosdrecht, A.A

Volltext

A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia von Zeijlemaker, W, Kelder, A, Oussoren-Brockhoff, Y J M, Scholten, W J, Snel, A N, Veldhuizen, D, Cloos, J, Ossenkoppele, G J, Schuurhuis, G J

Volltext

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center von Walter, R B, Othus, M, Burnett, A K, Löwenberg, B, Kantarjian, H M, Ossenkoppele, G J, Hills, R K, Ravandi, F, Pabst, T, Evans, A, Pierce, S R, Vekemans, M-C, Appelbaum, F R, Estey, E H

Volltext

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia von Zeijlemaker, W, Kelder, A, Oussoren-Brockhoff, Y J M, Scholten, W J, Snel, A N, Veldhuizen, D, Cloos, J, Ossenkoppele, G J, Schuurhuis, G J

Volltext

287 Validation of a flow cytometric scoring system for the prognostication of the myelodysplastic syndromes; A retrospective cohort study von Alhan, C, Westers, T.M, Cali, C, Ossenkoppele, G.J, van de Loosdrecht, A.A

Volltext

P49 The treatment of patients with Myelodysplastic Syndromes in an era of application of new treatment modalities in an outpatient setting requires a multidisciplinary approach von Eeltink, C, Ossenkoppele, G.J, van de Loosdrecht, A.A

Volltext

Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012 von Dinmohamed, A G, Visser, O, van Norden, Y, Blijlevens, N M A, Cornelissen, J J, Huls, G A, Huijgens, P C, Sonneveld, P, van de Loosdrecht, A A, Ossenkoppele, G J, Löwenberg, B, Jongen-Lavrencic, M

Volltext

286 The presence of aberrant myeloid progenitors predicts overall survival in intermediate-2 and high risk myelodysplastic syndromes upon treatment with azacitidine von Alhan, C, Westers, T.M, Eeltink, C, Cali, C, Huls, G, Ossenkoppele, G.J, van de Loosdrecht, A.A

Volltext

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results von le Coutre, P D, Giles, F J, Hochhaus, A, Apperley, J F, Ossenkoppele, G J, Blakesley, R, Shou, Y, Gallagher, N J, Baccarani, M, Cortes, J, Kantarjian, H M

Volltext

The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system von Alhan, C, Westers, T M, Cremers, E M P, Cali, C, Witte, B I, Ossenkoppele, G J, van de Loosdrecht, A A

Volltext

Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40 von Rijneveld, A W, van der Holt, B, Daenen, S M G J, Biemond, B J, de Weerdt, O, Muus, P, Maertens, J, Mattijssen, V, Demuynck, H, Legdeur, M C J C, Wijermans, P W, Wittebol, S, Spoelstra, F M, Dekker, A W, Ossenkoppele, G J, Willemze, R, Cornelissen, J J

Volltext

MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia von de Leeuw, D C, Verhagen, H J M P, Denkers, F, Kavelaars, F G, Valk, P J M, Schuurhuis, G J, Ossenkoppele, G J, Smit, L

Volltext

P093 Changes in the flowcytometric dysplasia score during treatment with erythropoietin/G-CSF reflect responses in low/int-I risk myelodysplastic syndromes von Westers, T.M, Chamuleau, M.E.D, Westra, A.H, Dräger, A.M, Ossenkoppele, G.J, van de Loosdrecht, A.A

Volltext